Evidence Level:Sensitive: A2 - Guideline
New
Excerpt:Invasive Breast Cancer: HER-2 negative...Other Recommended Regimens…Docetaxel…
Evidence Level:Sensitive: C2 – Inclusion Criteria
New
Title:
Assessment of the Efficacy of a Neoadjuvant Combination: "Chemotherapy-targeted Therapy" in Breast Cancer.
Excerpt:...- HR negative and HER 2 negative....
Evidence Level:Sensitive: C2 – Inclusion Criteria
New
Title:
Adjuvant Systemic Treatment for (ER)-Positive HER2-negative Breast Carcinoma in Women Over 70 According to Genomic Grade (GG): Chemotherapy + Endocrine Treatment Versus Endocrine Treatment
Excerpt:...- HER2 negative status (i.e. IHC score 0 or 1+, or IHC score 2+ and FISH/SISH/CISH negative), -...
More C2 evidence
![](/assets/chevron-circle-down-solid.svg)
Evidence Level:Sensitive: C2 – Inclusion Criteria
New
Title:
Utidelone Versus Docetaxel in HER2-negative Locally Advanced or Metastatic Breast Cancer
Excerpt:...- The primary tumor and metastases (if re-biopsy was performed) were both HER2-negative;...
Evidence Level:Sensitive: C2 – Inclusion Criteria
New
Title:
Study of LDE225 (Sonidegib) in Combination With Docetaxel in Triple Negative (TN) Advanced Breast Cancer (ABC) Patients
Excerpt:...Hormonal Receptor (HR) negative defined as < 1% positive cells by Immunohistochemistry (IHC) for both Estrogen Receptor (ER) and Progesterone Receptor (PgR), and HER2 negative defined as in situ hybridization (ISH) negative or IHC 0 or 1+ in the absence of ISH (...
Evidence Level:Sensitive: C2 – Inclusion Criteria
New
Title:
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
Excerpt:...- Participants' primary and/or metastatic tumor is human epidermal growth factor receptor 2 (HER2)-negative by fluorescence in-situ hybridization (FISH) or chromogenic in-situ hybridization (CISH) or 0, 1+ overexpression by immunohistochemistry (IHC)...
Evidence Level:Sensitive: C2 – Inclusion Criteria
New
Title:
Docetaxel With or Without a Phytochemical in Treating Patients With Breast Cancer
Excerpt:...- HER2-negative disease...
Evidence Level:Sensitive: C2 – Inclusion Criteria
New
Title:
Docetaxel 2-weeks Regimen in the Treatment of HER2 Negative Metastatic Breast Cancer
Evidence Level:Sensitive: C2 – Inclusion Criteria
New
Title:
A Study Of Docetaxel Or Docetaxel Plus PF-3512676 To Treat Patients With Advanced Breast Cancer.
Excerpt:...- Patients with HER-2 negative disease with documented disease progression after (neo)adjuvant treatment with an anthracycline-based chemotherapy regimen....
Evidence Level:Sensitive: C2 – Inclusion Criteria
New
Title:
A Study of YM155 Plus Docetaxel as First-Line Treatment in Subjects With HER2 Negative Metastatic Breast Cancer
Excerpt:...- Histologically- or cytologically-proven adenocarcinoma of the breast that is HER2 negative....
Evidence Level:Sensitive: C2 – Inclusion Criteria
New
Title:
Prospective, open, multicenter, single arm clinical study of atapatinib combined with docetaxel in the treatment of HER2 negative breast cancer with a first-line to three line chemotherapy failure
Excerpt:...1) aged 18-70 year old female patients; 2) at least one target can be defined according to the evaluation criteria of solid tumor efficacy (RECIST 1.1), and there is no radiation therapy (or other local treatment) in the target area unless radiotherapy or other local treatment is completed; 3) the recurrence and metastatic HER -2 negative breast cancer was confirmed by pathology; the HER-2 negative criterion was HER-2 (- / + +). ...